Abstract
Background/Aim
The miR-181 family plays an important role in the regulation of various cellular functions. However, whether miR-181b-5p mediates hepatic insulin resistance remains unknown. In this study, we investigated the effect of miR-181b-5p on the regulation of hepatic glycogen synthesis.
Methods
The miR-181b-5p levels in the livers of diabetic mice were detected by real-time PCR. The glycogen levels and AKT/GSK pathway activation were examined in human hepatic L02 cells and HepG2 cells transfected with miR-181b-5p mimic or inhibitor. The potential target genes of miR-181b-5p were evaluated using a luciferase reporter assay and Western blot analysis. EGR1-specific siRNA and pCMV-EGR1 were used to further determine the role of miR-181b-5p in hepatic glycogen synthesis in vitro. Hepatic inhibition of miR-181b-5p in mice was performed using adeno-associated virus 8 (AAV8) vectors by tail intravenous injection.
Results
The miR-181b-5p levels were significantly decreased in the serum and livers of diabetic mice as well as the serum of type 2 diabetes patients. Importantly, inhibition of miR-181b-5p expression impaired the AKT/GSK pathway and reduced glycogenesis in hepatocytes. Moreover, upregulation of miR-181b-5p reversed high-glucose-induced suppression of glycogenesis. Further analysis revealed that early growth response 1 (EGR1) was a downstream target of miR-181b-5p. Silencing of EGR1 expression rescued miR-181b-5p inhibition-reduced AKT/GSK pathway activation and glycogenesis in hepatocytes. Hepatic inhibition of miR-181b-5p led to insulin resistance in C57BL/6 J mice.
Conclusion
We demonstrated that miR-181b-5p contributes to glycogen synthesis by targeting EGR1, thereby regulating PTEN expression to mediate hepatic insulin resistance.
Similar content being viewed by others
References
Yore MM, Syed I, Moraes-Vieira PM, et al. Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects. Cell. 2014;159:318–332.
Perry RJ, Camporez JG, Kursawe R, et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell. 2015;160:745–758.
da Silva IV, Rodrigues JS, Rebelo I, et al. Revisiting the metabolic syndrome: the emerging role of aquaglyceroporins. Cell Mol Life Sci. 2018;75:1973–1988.
Williams MD, Mitchell GM. MicroRNAs in insulin resistance and obesity. Exp Diabetes Res. 2012:484696.
Sud N, Zhang H, Pan K, et al. Aberrant expression of microRNA induced by high-fructose diet: implications in the pathogenesis of hyperlipidemia and hepatic insulin resistance. J Nutr Biochem. 2017;43:125–131.
Duan LJ, Ding M, Hou LJ, et al. Long noncoding RNA TUG1 alleviates extracellular matrix accumulation via mediating microRNA-377 targeting of PPARγ in diabetic nephropathy. Biochem Bioph Res Co. 2017;484:598–604.
Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384–388.
Raffort J, Hinault C, Dumortier O, et al. Circulating microRNAs and diabetes: potential applications in medical practice. Diabetologia. 2015;58:1978–1992.
Ye D, Zhang TB, Lou GH, et al. Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients. Life Sci. 2018;208:201–207.
Trajkovski M, Hausser J, Soutschek J, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011;474:649–653.
Liang J, Liu C, Qiao A, et al. MicroRNA-29a-c decrease fasting blood glucose levels by negatively regulating hepatic gluconeogenesis. J Hepatol. 2013;58:535–542.
Fu X, Dong B, Tian Y, et al. MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids. J Clin Invest. 2015;125:2497–2509.
Wang SY, Wang LL, Dou L, et al. MicroRNA 152 regulates hepatic glycogenesis by targeting PTEN. FEBS J. 2016;283:1935–1946.
Dou L, Wang SY, Sui XF, et al. MiR-301a mediates the effect of IL-6 on the AKT/GSK pathway and hepatic glycogenesis by regulating PTEN expression. Cell Physiol Biochem. 2015;35:1413–1424.
Dou L, Wang SY, Sun L, et al. Mir-338-3p mediates Tnf-A-induced hepatic insulin resistance by targeting PP4r1 to regulate PP4 expression. Cell Physiol Biochem. 2017;41:2419–2431.
Li WC, Ralphs KL, Tosh D. Isolation and culture of adult mouse hepatocytes. Methods Mol Biol. 2010;633:185–196.
Virolle T, Adamson ED, Baron V, et al. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol. 2001;3:1124–1128.
Basu R, Chandramouli V, Dicke B, et al. Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis. Diabetes. 2005;54:1942–1948.
Wang C, Wan S, Yang T, et al. Increased serum microRNAs are closely associated with the presence of microvascular complications in type 2 diabetes mellitus. Sci Rep. 2016;6:20032.
Paul P, Chakraborty A, Sarkar D, et al. Interplay between miRNAs and human diseases. J Cell Physiol. 2018;233:2007–2018.
Fernandez-Valverde SL, Taft RJ, Mattick JS. MicroRNAs in beta-cell biology, insulin resistance, diabetes and its complications. Diabetes. 2011;60:1825–1831.
Chen CZ, Li L, Harvey F, et al. MicroRNAs modulate mematopoietic lineage differentiation. Science. 2004;303:83–86.
Ghorbani S, Talebi F, Chan WF, et al. MicroRNA-181variants regulate T cell phenotype in the context of autoimmune neuroinflammation. Front Immunol. 2017;8:758.
Strotbek M, Schmid S, Sanchez-Gonzalez I, et al. miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer. Int J Cancer. 2017;140:2310–2320.
Wang H, Tao T, Yan W, et al. Upregulation of miR-181 s reverses mesenchymal transition by targeting KPNA4 in glioblastoma. Sci Rep. 2015;5:13072.
Wang JB, Xie CM, Pan SH, et al. N-myc downstream-regulated gene 2 inhibits human cholangiocarcinoma progression and is regulated by leukemia inhibitory factor/MicroRNA-181c negative feedback pathway. Hepatology. 2016;64:1606–1622.
Chu B, Wu T, Miao L, et al. MiR-181a regulates lipid metabolism via IDH1. Sci Rep. 2015;5:8801.
Chen Z, Shi H, Sun S, et al. MicroRNA-181b suppresses TAG via target IRS2 and regulating multiple genes in the Hippo pathway. Exp Cell Res. 2016;348:66–74.
Sands MS. AAV-mediated liver-directed gene therapy. Methods Mol Biol. 2011;807:141–157.
Wang LL, Wang H, Bell P, et al. Systematic evaluation of AAV vectors for liver directed gene transfer in murine models. Mol Ther. 2010;18:118–125.
Sun X, Lin J, Kang S, et al. MicroRNA-181b improves glucose homeostasis and insulin sensitivity by regulating endothelial function in white adipose tissue. Circ Res. 2016;118:810–821.
Du XL, Yang Y, Xu C, et al. Upregulation of miR-181a impairs hepatic glucose and lipid homeostasis. Oncotarget. 2017;8:91362–91378.
Yao J, Mackman N, Edgington TS, et al. Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors. J Biol Chem. 1997;272:17795–17801.
Derdak Z, Villegas KA, Wands JR. Early growth response-1 transcription factor promotes hepatic fibrosis and steatosis in long-term ethanol-fed Long-Evans rats. Liver Int. 2012;32:761–770.
Lau MT, Klausen C, Leung PC. E-cadherin inhibits tumor cell growth by suppressing PI3 K/Akt signaling via beta-catenin-Egr1-mediated PTEN expression. Oncogene. 2011;30:2753–2766.
Wang D, Guan MP, Zheng ZJ, et al. Transcription factor Egr1 is involved in high hlucose-induced proliferation and fibrosis in rat glomerular mesangial cells. Cell Physiol Biochem. 2015;36:2093–2107.
Yoon TM, Kim SA, Lee DH, et al. EGR1 regulates radiation-induced apoptosis in head and neck squamous cell carcinoma. Oncol Rep. 2015;33:1717–1722.
Shen N, Yu X, Pan FY, et al. An early response transcription factor, Egr-1, enhances insulin resistance in type 2 diabetes with chronic hyperinsulinism. J Biol Chem. 2011;286:14508–14515.
Yu X, Shen N, Zhang ML, et al. Egr-1 decreases adipocyte insulin sensitivity by tilting PI3 K/Akt and MAPK signal balance in mice. EMBO J. 2011;30:3754–3765.
Shen N, Jiang S, Lu J, et al. The constitutive activation of Egr-1/C/EBPa mediates the development of type 2 diabetes mellitus by enhancing hepatic gluconeogenesis. Am J Pathol. 2015;185:513–523.
Acknowledgments
This work was supported by grants from the National Natural Science Foundation of China (81700709 and 81502284), the Research Foundation of Jilin Provincial Science & Technology Development (20180520105JH and 20170414028GH), the Fundamental Research Funds for the Central Universities (2412017DQ015), and the Changchun Science and Technology Bureau (17YJ003-1).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors of this study declare that no conflicts of interest exist.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Wang, S., Liang, C., Ai, H. et al. Hepatic miR-181b-5p Contributes to Glycogen Synthesis Through Targeting EGR1. Dig Dis Sci 64, 1548–1559 (2019). https://doi.org/10.1007/s10620-018-5442-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-018-5442-4